Weil advised WindRose Health Investors (WindRose), a leading healthcare-focused private equity firm, in the closing of its sixth fund, WindRose Health Investors VI, with more than $1.4 billion in limited partner and general partner commitments. The fund closed at its hard cap and significantly exceeded the size of its $705 million predecessor fund.

For more than 20 years, WindRose has focused on investing in businesses that operate in the services sector of healthcare. WindRose aims to invest in companies that are improving quality and enhancing efficiency in healthcare.

"We are grateful to have earned the trust of a world-class group of investors and will work diligently on their behalf to execute our strategy," said Oliver T. Moses, WindRose Managing Partner. "As a team that has built an extensive track record in healthcare, we believe that WindRose is well-positioned to identify innovative companies and provide them with resources that deliver enhanced growth and differentiated results for our investors." 

The Weil team that advised WindRose was led by Private Funds partner Stephanie E. Srulowitz. The team also included Tax partner Robert Frastai, Private Funds counsel Semhar Woldai and associate Adam Ofman.